Cronos Group Interest Expense 2011-2026 | CRON

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Cronos Group

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-241 K	-301 K	1.03 M	13 K	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.03 M	-301 K	125 K

Quarterly Interest Expense Cronos Group

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10 K	-283 K	-1 K	43 K	-315 K	248 K	-652 K	966 K	-26 K	85 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
966 K	-652 K	7.5 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Cumberland Pharmaceuticals CPIX	496 K	$ 5.47	11.18 %	$ 81.3 M	USA
Evoke Pharma EVOK	501 K	-	-	$ 36.6 M	USA
AcelRx Pharmaceuticals ACRX	134 K	-	7.5 %	$ 6.35 M	USA
DURECT Corporation DRRX	2.4 M	-	-	$ 50.1 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Harrow Health HROW	47 K	$ 31.21	1.13 %	$ 1.15 B	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Organogenesis Holdings ORGO	-5 K	$ 2.41	-6.95 %	$ 305 M	USA
Bausch Health Companies BHC	-28 M	$ 5.42	-0.55 %	$ 1.98 B	Canada
Pacira BioSciences PCRX	-373 K	$ 22.64	-3.78 %	$ 1.05 B	USA
Solid Biosciences SLDB	824 K	$ 6.92	-9.31 %	$ 606 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.04	-2.8 %	$ 112 M	Canada
Tilray TLRY	46.6 M	$ 5.32	-3.27 %	$ 3.29 B	Canada
Sonoma Pharmaceuticals SNOA	-10 K	$ 1.09	-7.63 %	$ 1.35 M	USA
Jupiter Wellness JUPW	152 K	-	-	$ 33.6 M	USA
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Evolus EOLS	-539 K	$ 6.5	-1.22 %	$ 419 M	USA
Sundial Growers SNDL	81 K	$ 1.43	-2.05 %	$ 3.37 M	Canada
Veru VERU	768 K	$ 2.11	0.96 %	$ 30.9 M	USA
Emergent BioSolutions EBS	87.9 M	$ 7.94	-3.29 %	$ 407 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
cbdMD YCBD	34.3 K	$ 0.77	-6.44 %	$ 3.1 M	USA
Assertio Holdings ASRT	2.78 M	$ 23.32	-	$ 149 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 6.9	-7.01 %	$ 272 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	3.13 M	$ 0.74	-4.0 %	$ 37 M	USA
Viatris VTRS	471 M	$ 16.48	-4.52 %	$ 19.2 B	USA
Zomedica Corp. ZOM	-144 K	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	27 K	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-623 K	$ 0.79	-0.55 %	$ 28.4 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	27.3 K	$ 1.04	-16.13 %	$ 4.46 M	China
TherapeuticsMD TXMD	300 K	$ 2.0	0.5 %	$ 23.1 M	USA